회사의 펀더멘털은 비교적 아주 건전한한 편입니다. 회사의 밸류에이션은 적정하게 평가된으로 간주됩니다. 기관의 인지도는 매우 높은입니다. 주식시장에서 부진한 성과에도 불구하고, 회사는 강한 펀더멘털을 보이고 있습니다. 주가는 지지선과 저항선 사이에서 횡보하고 있으며, 범위 매매 기반의 스윙 트레이딩에 적합한 상황입니다.
주식 점수
관련 정보
산업 순위
278 / 506
전체 순위
466 / 4720
산업
생명공학 및 의료 연구
저항선 & 지지선
데이터 없음
레이더 차트
현재 가격
과거
분석가 목표가
0
명의 분석가를 기준으로
--
현재 등급
--
목표 가격
--
상승 여력
면책 조항: 애널리스트 평가 및 목표 주가는 정보 제공을 위한 목적으로 LSEG에서 제공되며, 투자 조언으로 간주되지 않습니다.
기업 하이라이트
강점위험 요소
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
고수익 성장
회사의 순이익은 업계 선두를 달리고 있으며, 최근 연간 순이익은 미화 267.47에 달합니다.
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.